<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diffuse intrinsic pontine glioma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diffuse intrinsic pontine glioma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Diffuse intrinsic pontine glioma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karen J Marcus, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Matthias A Karajannis, MD, MS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Y Wen, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amar Gajjar, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Helen A Shih, MD, MS, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Brainstem gliomas are characterized by heterogeneous biologic behavior, ranging from low-grade tumors needing little treatment to those that are rapidly fatal despite aggressive therapy [<a href="#rid1">1,2</a>]. Prognosis and treatment depend upon both the clinical symptoms and their duration, the location of the tumor within the brainstem, and, increasingly, the mutational profile.</p><p>Approximately 80 percent of pediatric brainstem gliomas arise within the pons, while the remaining 20 percent arise in the medulla, midbrain, or cervicomedullary junction  (<a class="graphic graphic_figure graphicRef53866" href="/d/graphic/53866.html" rel="external">figure 1</a>) [<a href="#rid3">3-8</a>]. The majority of pontine tumors are diffuse intrinsic brainstem gliomas, which are usually high grade, locally infiltrative, and have a uniformly poor prognosis [<a href="#rid9">9</a>]. Histologically, these tumors are usually World Health Organization (WHO) grade 3 (anaplastic) astrocytomas or glioblastoma (WHO grade 4). However, patients with WHO grade 2 tumors identified by biopsy do not have an improved prognosis. (See  <a class="medical medical_review" href="/d/html/5211.html" rel="external">"Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors"</a>.)</p><p>By contrast, most nonpontine tumors involving the cervicomedullary junction and tectum, as well as focal, cystic, and dorsal exophytic lesions, are low-grade astrocytomas, mostly grade 1 pilocytic astrocytomas [<a href="#rid6">6</a>]. These are discrete, well-circumscribed tumors, often without evidence of locally invasive growth or edema [<a href="#rid10">10</a>]. Approximately 10 to 20 percent of nonpontine gliomas will be high grade and are treated similarly to diffuse intrinsic pontine gliomas.</p><p>Diffuse intrinsic pontine gliomas will be reviewed here. Gliomas arising from other sites within the brainstem are discussed separately. (See  <a class="medical medical_review" href="/d/html/5191.html" rel="external">"Focal brainstem glioma"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Gliomas arising in the brainstem (midbrain, pons, and medulla oblongata) account for 10 to 20 percent of all central nervous system tumors in children and approximately one-third of high-grade gliomas in children [<a href="#rid11">11</a>]. Brainstem gliomas are more common in children than adults [<a href="#rid3">3,4,12,13</a>]. In the United States, for example, there are approximately 300 pediatric cases and 100 adult cases reported each year. In children, the median age at diagnosis is five to nine years, and there is a slight female sex predominance [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H3"><span class="h1">PATHOLOGY</span></p><p class="headingAnchor" id="H992298657"><span class="h2">Histopathology and grade</span><span class="headingEndMark"> — </span>The most commonly used classification system for central nervous system tumors is that of the World Health Organization (WHO) [<a href="#rid14">14</a>]. Astrocytomas account for greater than 95 percent of all brainstem lesions. Most centers classify these tumors based on the WHO criteria, which encourage use of integrated and layered diagnoses to accommodate histologic and genetic parameters into a single diagnosis  (<a class="graphic graphic_algorithm graphicRef134946" href="/d/graphic/134946.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef134980" href="/d/graphic/134980.html" rel="external">table 1</a>) (see  <a class="medical medical_review" href="/d/html/5211.html" rel="external">"Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors", section on 'Histopathologic and molecular classification'</a>). For diffuse intrinsic pontine tumors, clinical and radiographic characteristics continue to be the most important predictors of outcome.</p><p>When biopsied, diffuse intrinsic pontine gliomas are usually high-grade astrocytomas, although up to one-quarter appear low grade on classic histologic features, and nearly all tumors progress rapidly. Importantly, histopathologic grade does not correlate with prognosis in diffuse intrinsic pontine gliomas, and even low-grade diffuse pontine lesions behave aggressively and carry a similarly poor prognosis compared with high-grade tumors.</p><p>Glial tumors of the pons have rarely metastasized to distant sites at the time of diagnosis. Instead, they tend to progress along established fiber tracts, especially into the thalamus and cerebellum. Spinal seeding is rare but can be observed in the end stages of the disease [<a href="#rid15">15,16</a>]. With an average life expectancy of less than a year, the absence of metastatic disease may be the result of the rapidly fatal course of the primary tumor, rather than a lack of the metastatic potential of these tumors.</p><p>Tumors of the cervicomedullary junction, as well as focal and dorsal exophytic lesions, tend to be low grade based upon the WHO classification. When a high-grade component of one of these lesions is observed, the tumor tends to behave similarly to high-grade glial lesions in other parts of the central nervous system.</p><p class="headingAnchor" id="H1035240859"><span class="h2">Molecular pathogenesis</span><span class="headingEndMark"> — </span>Significant insights have been gained into the molecular biology of diffuse intrinsic pontine gliomas using biopsy tissue and autopsy material [<a href="#rid17">17,18</a>]. Despite similar histopathology, adult and pediatric diffuse gliomas are now recognized to contain distinct underlying genetic events.</p><p class="bulletIndent1"><span class="glyph">●</span>Mutually exclusive mutations in either <em>H3F3A, </em>one of two genes<em> </em>encoding the histone H3.3 variant, or <em>HIST3H1B, </em>one of several genes encoding histone H3.1, have been identified in nearly 80 percent of diffuse intrinsic pontine gliomas and appear to be present in all tumor cells [<a href="#rid19">19-21</a>]. Both mutations involve a substitution of lysine 27 to methionine (H3 K27M), which results in altered binding of mutant histone H3 to polycomb repressive complex 2 (PRC2), a key developmental regulator of gene expression [<a href="#rid22">22</a>]. <em>H3F3A</em>-mutant tumors may also harbor mutations in protein phosphatase, magnesium/manganese-dependent (<em>PPM1D</em>), which alter the DNA damage response pathway [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Amplification and overexpression of the platelet-derived growth factor receptor (PDGFR) A and c-Met proteins seem to be important molecular events in the transformation of cells to a malignant phenotype [<a href="#rid24">24</a>], seen more commonly in H3.3-mutant tumors. Activating mutations in phosphatidylinositol 3-kinase (<em>PI3K</em>) are identified in approximately 15 percent of diffuse intrinsic pontine gliomas [<a href="#rid25">25</a>] and seem to be more common in H3.1-mutant tumors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent somatic mutations in activin A receptor, type 1 (<em>ACVR1</em>), a gene that encodes a bone morphogenetic protein (BMP) type 1 receptor, have been identified in up to one-third of pediatric diffuse intrinsic pontine gliomas [<a href="#rid26">26-29</a>]. Mutations result in activation of the BMP pathway and increased expression of a variety of downstream effectors, including Smad proteins and members of the <em>ID</em> gene family, which may represent potential therapeutic targets. These mutations are often associated with concurrent mutations in <em>PI3K</em> [<a href="#rid25">25,28</a>] and the H3.1 gene [<a href="#rid28">28,29</a>] and may be associated with slightly better prognosis [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mutations in isocitrate dehydrogenase type 1 (<em>IDH1</em>) or type 2 (<em>IDH2</em>), which define a large proportion of adult grade 2 and 3 diffuse gliomas, are extremely rare in pediatric diffuse intrinsic pontine gliomas [<a href="#rid31">31,32</a>]. By contrast, <em>IDH1/2</em> mutations, mostly non-R132H variants, may be present in up to one-quarter of adult brainstem gliomas, are associated with improved prognosis [<a href="#rid32">32,33</a>], and may benefit from adjuvant chemotherapy in addition to radiation therapy [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/d/html/5211.html" rel="external">"Classification and pathologic diagnosis of gliomas, glioneuronal tumors, and neuronal tumors", section on 'IDH1/IDH2 mutation'</a>.)</p><p></p><p>Relevant mouse models based on these molecular insights have been developed to aid in the identification of targeted therapies for diffuse intrinsic pontine gliomas. (See <a class="local">'Investigational therapies'</a> below.)</p><p class="headingAnchor" id="H2394381212"><span class="h2">Diffuse midline glioma, H3 K27-altered</span><span class="headingEndMark"> — </span>Diffuse midline glioma, H3 K27-altered was a new diagnostic entity as of the 2016 revised version of the WHO classification of brain tumors [<a href="#rid35">35</a>]. As discussed above, approximately 80 percent of biopsied diffuse intrinsic pontine gliomas harbor mutations at position K27 in one of several histone-encoding genes. (See <a class="local">'Molecular pathogenesis'</a> above.)</p><p>Per the WHO classification, H3 K27-altered midline gliomas are high-grade gliomas, by definition WHO grade 4, associated with local infiltration and a poor prognosis, even when they have the histologic appearance of a low-grade glioma [<a href="#rid14">14,36</a>]. Although the pons is the most common location, H3 K27-altered gliomas also occur in the thalamus, spinal cord, and other midline sites and can affect both children and adults [<a href="#rid33">33,37,38</a>]. The natural history of these tumors in locations outside the brainstem and in adults is not yet well defined and may be more heterogeneous than that of H3 K27-altered diffuse intrinsic pontine gliomas [<a href="#rid39">39,40</a>].</p><p>Importantly, H3 K27-altered diffuse midline glioma is a pathologic diagnosis and is not synonymous with the clinical and radiologic entity of diffuse intrinsic pontine glioma, which does not require biopsy for diagnosis (and is often not biopsied) and behaves uniformly poorly, regardless of histologic grade or H3 K27M status.</p><p>Advanced sequencing techniques on circulating tumor cells in blood and cerebrospinal fluid may eventually aid in noninvasive identification of H3 K27-altered gliomas [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Diffuse intrinsic pontine gliomas can present with varied symptoms depending on the location of the lesion. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Cranial nerve palsies, long tract signs (eg, hemiparesis), and ataxia in over 50 percent of patients. Cranial nerves VI and VII are most commonly affected, but III, IV, IX, and X may also be involved.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hydrocephalus with elevated intracranial pressure (ICP) is observed in less than 10 percent of patients at presentation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Significant intratumoral hemorrhage can be present in approximately 6 percent of patients at the time of diagnosis, although small punctate hemorrhages can be seen in a high percentage of cases [<a href="#rid42">42</a>]. Symptomatic hemorrhage may eventually occur in up to 20 percent of children, usually in necrotic areas of tumor.</p><p></p><p>None of these symptoms are pathognomonic of diffuse intrinsic pontine gliomas. Other brainstem tumors can present with similar symptoms. (See  <a class="medical medical_review" href="/d/html/5191.html" rel="external">"Focal brainstem glioma"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Cervicomedullary tumors typically present with lower cranial nerve dysfunction and ataxia and have a prolonged clinical course, often progressing over years rather than days or weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Focal tumors tend to interfere with the cranial nerves adjacent to the site of origin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unlike other brainstem tumors, tectal plate lesions present with hydrocephalus in over 90 percent of cases. Although these tumors are rarely biopsied, those that have been studied are almost always low-grade astrocytomas.</p><p></p><p>In contrast to focal brainstem gliomas, diffuse intrinsic pontine gliomas usually present with a short duration of symptoms (typically less than three months). The duration of symptoms in the context of classic radiographic findings is an important predictor of prognosis in brainstem tumors. Patients with symptoms of greater than six months' duration at the time of diagnosis tend to do much better than patients with a shorter duration. (See  <a class="medical medical_review" href="/d/html/5191.html" rel="external">"Focal brainstem glioma", section on 'Clinical features'</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">NEUROIMAGING</span><span class="headingEndMark"> — </span>Imaging studies, particularly magnetic resonance imaging (MRI) and, less frequently, computed tomography (CT), are the standard method of diagnosis and classification for brainstem tumors [<a href="#rid6">6</a>]. The brainstem is one of the most eloquent areas of the brain, making biopsy difficult in centers without expertise in this area. (See <a class="local">'Surgery'</a> below.)</p><p>Diffuse intrinsic pontine gliomas have a typical appearance on CT scans with hypodense to isodense appearance and variable contrast enhancement. Calcium is rarely identified within the tumor. MRI is superior to CT for defining these lesions. On MRI, diffuse pontine lesions are expansile, typically hypointense on T1- and hyperintense on T2-weighted images  (<a class="graphic graphic_diagnosticimage graphicRef100714" href="/d/graphic/100714.html" rel="external">image 1</a>).</p><p>High-grade tumors typically invade adjacent areas including the medulla or midbrain. Axial growth is commonly observed through the cerebellar peduncles and into the cerebellum, and the tumors expand the pons, instead of displacing it. They frequently have exophytic components into the prepontine cistern and often encircle the basilar artery. On sagittal images, the tumors appear to respect the pontomedullary boundary.</p><p>Contrast enhancement within the tumors can be variable and may be ring-enhancing with central areas of necrosis. The apparent well-circumscribed appearance of ring-enhancing lesions on MRI is often not confirmed at the time of surgery or autopsy and does not indicate a lower-grade lesion or more benign clinical course. Many diffuse pontine tumors have no contrast enhancement. Tumors that demonstrate diffuse uniform enhancement are more likely low grade, are usually associated with prolonged symptoms, and may have a better outcome.</p><p>Magnetic resonance spectroscopy (MRS) with estimation of choline-to-N-acetylaspartate (Cho:NAA) ratios is another noninvasive method that can be used to support the diagnosis and may provide prognostic information [<a href="#rid43">43,44</a>]. In one series, children with a maximum Cho:NAA ratio greater than 4.5 had a median survival of 22 weeks, and all 13 patients died by 63 weeks. By contrast, the projected survival of patients with a Cho:NAA ratio ≤4.5 was significantly better, 50 percent at 63 weeks [<a href="#rid45">45</a>].</p><p>Other potentially useful techniques to further assist in imaging-based diagnoses for brainstem tumors include rapid diffusion MRI, thallium single-photon emission computed tomography (SPECT) [<a href="#rid46">46</a>], and positron emission tomography (PET) [<a href="#rid47">47</a>]. As an example, 111In-pentetreotide binds the somatostatin receptor, which is frequently expressed in gliomas. Scanning with this agent can both help support the diagnosis and, if labeled, potentially target radiation therapy to these lesions [<a href="#rid48">48</a>]. While these methods continue to undergo further development and refinement, they are being used more frequently to assist MRI-based diagnosis, particularly in difficult or unclear cases.</p><p>While MRI has become the standard method of evaluation of diffuse intrinsic pontine gliomas, the heterogeneous signal characteristics of these lesions and interobserver variability make serial assessment difficult [<a href="#rid49">49</a>]. Evaluation of new therapies should therefore be based upon overall survival rather than MRI changes whenever possible [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H8"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Advances in imaging techniques and the difficulty in obtaining an adequate biopsy sample make the interpretation of the imaging studies critical in the differential diagnosis. If imaging findings are typical, biopsy is not usually necessary to confirm the diagnosis and should only be performed in the context of a formal clinical trial [<a href="#rid51">51</a>].</p><p>Patients with a long duration of symptoms and atypical clinical or imaging findings have an increased likelihood of having a lesion other than diffuse intrinsic pontine glioma. Such patients, as well as adolescents and adults, should be considered for biopsy, given the possibility of an IDH-mutant glioma. (See <a class="local">'Surgery'</a> below.)</p><p class="headingAnchor" id="H26802734"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>Vascular malformations, encephalitis, rare parasitic cysts, demyelinating disorders (eg, multiple sclerosis), and hamartomas in patients with neurofibromatosis are the most common causes of nonneoplastic lesions in the brainstem. Rare examples of metastases from extracranial carcinomas in adults have also been reported in the pons [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H9"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The management of a patient with a diffuse intrinsic pontine glioma includes control of peritumoral edema, as well as specific measures directed at the tumor (surgery, radiation therapy, and chemotherapy). Participation in clinical trials is encouraged, particularly as the molecular pathogenesis of these tumors is unravelled and targeted therapies begin to enter clinical trials. (See <a class="local">'Molecular pathogenesis'</a> above and <a class="local">'Investigational therapies'</a> below.)</p><p class="headingAnchor" id="H10"><span class="h2">Glucocorticoids</span><span class="headingEndMark"> — </span>The administration of glucocorticoids (eg, <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>) is an important initial step in the treatment of patients with high-grade brainstem tumors. Peritumoral edema often contributes prominently to symptoms, which can improve rapidly after steroid therapy. Although steroids do not treat the underlying problem, improved clinical performance can be an important matter for quality of life in patients with a limited life span.</p><p>Unfortunately, many patients require prolonged administration of <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>, resulting in significant steroid-related complications. In some cases, <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>, a monoclonal antibody against vascular endothelial growth factor (VEGF), has been used to modulate peritumoral edema without the complications of glucocorticoids [<a href="#rid53">53</a>]. (See  <a class="medical medical_review" href="/d/html/5182.html" rel="external">"Management of vasogenic edema in patients with primary and metastatic brain tumors", section on 'Refractory edema'</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Surgery</span><span class="headingEndMark"> — </span>Unless the clinical or imaging picture is atypical, surgery is usually not recommended in children with a clinical diagnosis of diffuse brainstem glioma outside of formal clinical trials [<a href="#rid54">54</a>]. The morbidity associated with surgery in this eloquent region of the brain and the sampling error associated with biopsies preclude routine biopsy to identify patients with lesions that are not high-grade astrocytomas [<a href="#rid10">10,55,56</a>]. Pontine biopsy should only be performed by surgeons with expertise in this procedure and ideally in the context of a clinical trial where the analysis will influence therapy [<a href="#rid51">51</a>].</p><p>Adults are more likely to benefit from a biopsy. In this setting, determining the tissue diagnosis may improve prognostication and direct therapy, such as in the case of IDH-mutant glioma. In addition, up to 30 percent of biopsied patients had a diagnosis other than astrocytoma (eg, lymphoma, ependymoma, or infection) in studies that were completed both before and after availability of MRI [<a href="#rid57">57,58</a>].</p><p>Given the hazards of the surgical approach and rarity of brainstem lesions, referral to a highly specialized and dedicated neurosurgical team should be made before treatment is initiated, particularly for lesions that lack some of the classic clinical and/or imaging features [<a href="#rid59">59</a>].</p><p>Advances in neurosurgical techniques have permitted biopsy of diffuse intrinsic pontine gliomas to be performed safely [<a href="#rid51">51,60-62</a>]. Pretherapy biopsy is being performed in the context of formal clinical trials to identify molecular pathways aberrant in these tumors and to use this information to guide treatment [<a href="#rid51">51</a>]. The feasibility and safety of biopsy has been demonstrated in a multicenter prospective study of 53 children with presumed diffuse intrinsic pontine glioma, in which 50 patients underwent stereotactic biopsy [<a href="#rid63">63</a>]. Two patients had procedural grade 3 adverse events (hypertension, apnea), and one patient developed a hemiparesis with incomplete recovery. There were no biopsy-related deaths, and all but one patient went on to receive planned radiation therapy at a median of 10 days postbiopsy. All but four samples yielded sufficient tissue for molecular analysis including O6-methylguanine-DNA methyltransferase (<em>MGMT</em>) methylation and whole genome sequencing.</p><p class="headingAnchor" id="H12"><span class="h2">Radiation therapy</span><span class="headingEndMark"> — </span>Radiation therapy is the only treatment that appears to alter the clinical course of diffuse intrinsic pontine gliomas. Despite multiple trials of dose escalation, altered fractionation, and radiosensitization, none of these modulations have been proven more effective than conventionally delivered radiation therapy.</p><p>Radiation therapy treatment fields are typically restricted to the tumor volume plus 1 to 2 cm of adjacent brainstem tissue. The standard treatment dose is 1.8 Gy daily given five days per week, to a total dose of between 54 and 59.4 Gy. Patients with severe symptoms may require urgent initiation of radiation therapy.</p><p>Although the degree of tumor shrinkage induced by radiation therapy can be dramatic, the response is generally transient, and patients are not cured by this approach. The median survival is approximately 10 months, and the two-year overall survival rate is less than 10 percent.</p><p>In older studies, the duration of response was correlated with the tumor grade, as well as the bulk of disease, although this has not been demonstrated in more recent studies [<a href="#rid64">64</a>]. The time to progression may be prolonged in patients with neurofibromatosis type 1 and in children as compared with older adults. Treatment failures are usually local and occur within the radiation therapy field. Although up to one-third of patients have evidence of central nervous system dissemination at the time of progression, most symptoms are referred to the primary site [<a href="#rid65">65,66</a>]. (See  <a class="medical medical_review" href="/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis"</a>.)</p><p>Due to the poor prognosis in these patients, hypofractionated radiation therapy has been evaluated to minimize the time spent in treatment [<a href="#rid67">67-71</a>]. In the largest of the trials among 253 children with newly diagnosed diffuse intrinsic pontine glioma, overall survival ranged from 8.2 to 9.6 months and was similar across three randomized treatment groups: 39 Gy in 13 fractions, 45 Gy in 15 fractions, and 54 Gy in 30 fractions [<a href="#rid71">71</a>]. Acute and delayed side effects and toxicities were also similar across groups.</p><p class="headingAnchor" id="H13"><span class="h2">Alternative radiation therapy techniques</span><span class="headingEndMark"> — </span>A number of alternative approaches have been used to try to improve the effectiveness of radiation therapy.</p><p class="bulletIndent1"><span class="glyph">●</span>Dose escalation, using multiple daily treatments with smaller than conventional fraction sizes, appeared to increase the radiographic response  (<a class="graphic graphic_table graphicRef59706" href="/d/graphic/59706.html" rel="external">table 2</a>). However, no overall survival advantage was observed, and many patients experienced significant toxicity due to prolonged steroid dependence [<a href="#rid72">72-74</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The addition of radiation sensitizers or concomitant or preradiation chemotherapy generally has failed to improve the time to disease progression [<a href="#rid75">75-78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Brachytherapy has been used to increase the delivery of radiation to the tumor after conventional-dose radiation therapy. In one report, there was minimal morbidity related to placement of 125-I in nine patients with diffuse intrinsic pontine glioma; however, this approach did not improve the response rate or survival outcome [<a href="#rid79">79</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stereotactic radiosurgery has been used in brainstem lesions, although great care is required because of the potential for radionecrosis in vital areas [<a href="#rid80">80</a>]. There are no data that this technique improves the outcome in this disease.</p><p></p><p>Fractionated reirradiation of pontine gliomas at the time of progression may be considered to temporarily extend palliation, although increased toxicities may result from this approach [<a href="#rid81">81,82</a>]. In a small prospective dose-escalation study, the lowest dose level (24 Gy in 12 fractions) was well tolerated and achieved imaging, clinical, and/or quality-of-life improvement in most patients; in all 12 patients, progression-free and overall survival from the start of reirradiation were 4.5 and 5.8 months, respectively [<a href="#rid83">83</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Chemotherapy</span><span class="headingEndMark"> — </span>Chemotherapy has been ineffective in the treatment of children with diffuse intrinsic pontine gliomas. Numerous treatment protocols, including single chemotherapy agents, multidrug combination regimens, and high-dose therapy with stem cell rescue, have all been tested in both adults and children without clear evidence of benefit [<a href="#rid84">84-86</a>].</p><p>Although <a class="drug drug_general" data-topicid="9699" href="/d/drug information/9699.html" rel="external">temozolomide</a> has become part of standard therapy for most adult patients with high-grade gliomas, testing in combination with radiation for newly diagnosed diffuse intrinsic pontine glioma has demonstrated no improvement in activity compared with radiation alone and is associated with increased risk for side effects and toxicity [<a href="#rid87">87-89</a>]. However, temozolomide should be considered for patients with isocitrate dehydrogenase (IDH)-mutant brainstem tumors given the demonstrated survival benefit in IDH-mutant 1p/19q non-codeleted anaplastic glioma [<a href="#rid34">34</a>].</p><p>Newer regimens have combined chemotherapy and biologic modifiers [<a href="#rid90">90</a>], but no regimen has demonstrated better activity than radiation therapy alone. Most of these efforts have been based upon results of studies in patients with high-grade gliomas arising elsewhere in brain.</p><p class="headingAnchor" id="H3133738929"><span class="h2">Investigational therapies</span><span class="headingEndMark"> — </span>A number of emerging preclinical insights are under investigation in clinical trials in diffuse intrinsic pontine glioma [<a href="#rid17">17,91-96</a>]. Promising examples include use of an H3 K27M-mutant vaccine [<a href="#rid97">97</a>] and use of chimeric antigen receptor (CAR)-expressing T cells with specific targeting against either GD2, a disialoganglioside that is highly expressed on the surface of H3 K27M-mutant glioma cells [<a href="#rid96">96</a>], or B7-H3, an immune regulatory protein expressed on diffuse intrinsic pontine glioma [<a href="#rid98">98</a>].</p><p>The investigational oral compound ONC201 is under active investigation in H3 K27-altered midline gliomas. The mechanism of action is not well defined but may involve mitochondrial metabolism and the stress response pathway [<a href="#rid99">99</a>]. In a molecularly unselected phase II trial of ONC201, a near-complete radiographic response was observed in a patient with a recurrent H3 K27M-mutant thalamic glioma [<a href="#rid100">100</a>]. A subsequent series of 18 patients with H3 K27M-mutant gliomas (including eight children with diffuse intrinsic pontine glioma) treated on a compassionate basis included 14 patients with recurrent disease after radiation therapy [<a href="#rid101">101</a>]. Among these patients, median progression-free survival was 14 weeks, and three adults remained on treatment and progression free with a median follow-up of 50 weeks. Follow-up of four children treated with adjuvant ONC201 after radiation is ongoing. Several phase II trials of ONC201 have been initiated based on these findings [<a href="#rid102">102</a>].</p><p>Local therapies are also being studied, including DNX-2401, an oncolytic adenovirus administered by catheter infusion into the cerebellar peduncle [<a href="#rid103">103</a>].</p><p>Studies of systemic checkpoint inhibitor immunotherapies have thus far shown no clear signal of efficacy [<a href="#rid104">104</a>].</p><p class="headingAnchor" id="H15"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The prognosis of diffuse intrinsic pontine glioma is poor, with a median overall survival of 10 to 11 months [<a href="#rid86">86,105-107</a>]. Five-year survival is less than 3 percent, and many long-term survivors have evidence of moderate or severe cognitive impairment, likely as a consequence of radiation therapy [<a href="#rid107">107,108</a>].</p><p>Several studies have suggested that younger patients (age &lt;3 years) and older patients (age &gt;10 years) may have a somewhat better prognosis [<a href="#rid105">105,108-111</a>]. Other favorable prognostic factors include long interval between the onset of symptoms and diagnosis, lack of pontine cranial nerve palsies, and atypical radiologic characteristics (eg, lack of enhancement) [<a href="#rid84">84,105,107,108,112,113</a>].</p><p>While both high- and low-grade diffuse pontine lesions do poorly in children, adults with low-grade histology may have a somewhat longer time to progression, although most eventually succumb to their disease [<a href="#rid114">114,115</a>].</p><p class="headingAnchor" id="H1949581343"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/130511.html" rel="external">"Society guideline links: Primary brain tumors"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Diffuse intrinsic pontine gliomas are rare tumors that are more frequent in young children than in adults, with a median age of onset of five to nine years. (See <a class="local">'Epidemiology'</a> above and <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Molecular pathogenesis</strong> – Nearly 80 percent of biopsied diffuse intrinsic pontine gliomas harbor H3 K27M mutations in one of several histone-encoding genes. Other important molecular changes in subsets of tumors include alterations in the platelet-derived growth factor receptor (PDGFR), <em>PI3K</em> mutations, and recurrent somatic mutations in <em>ACVR1</em>. (See <a class="local">'Molecular pathogenesis'</a> above and <a class="local">'Diffuse midline glioma, H3 K27-altered'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histopathology and grade</strong> – Histopathologic grade does not correlate with prognosis in diffuse intrinsic pontine gliomas, and even low-grade diffuse intrinsic pontine lesions behave aggressively and carry a similarly poor prognosis compared with high-grade tumors. (See <a class="local">'Histopathology and grade'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Because of their location in an eloquent area of the brain, diagnosis is usually based upon imaging studies  (<a class="graphic graphic_diagnosticimage graphicRef100714" href="/d/graphic/100714.html" rel="external">image 1</a>) and classic clinical features. Surgery or surgical biopsy is not routinely indicated, unless atypical features are present, IDH-mutant glioma is in the differential diagnosis, or patients are part of a formal clinical study. (See <a class="local">'Neuroimaging'</a> above and <a class="local">'Surgery'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – The management of a patient with a diffuse intrinsic pontine glioma includes control of peritumoral edema and radiation therapy. Participation in clinical trials is encouraged.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Glucocorticoids are used to control tumor-associated edema in symptomatic patients. (See  <a class="medical medical_review" href="/d/html/5182.html" rel="external">"Management of vasogenic edema in patients with primary and metastatic brain tumors", section on 'Symptomatic treatment'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We recommend external beam radiation therapy as the primary approach to antitumor therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Radiation therapy'</a> above.)</p><p></p><p class="bulletIndent2">Our typical approach is to give a total dose of 54 to 59.4 Gy, in fractions of 1.8 Gy five times per week. Alternative radiation therapy techniques (hyperfractionation, radiation sensitizers, brachytherapy) have not been demonstrated to improve outcomes.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chemotherapy does not have an established role in the management of patients with diffuse intrinsic pontine glioma. Currently, chemotherapy in conjunction with radiation therapy is considered investigational and should be provided in the context of a clinical trial.</p><p></p><p class="bulletIndent2">We recommend against use of <a class="drug drug_general" data-topicid="9699" href="/d/drug information/9699.html" rel="external">temozolomide</a> in patients with diffuse intrinsic pontine gliomas (<a class="grade" href="https://medilib.ir/uptodate/show/grade_3" rel="external">Grade 1C</a>). Two phase II multicenter trials have found no benefit compared with historical controls, and the risk of side effects and toxicity is increased compared with radiation alone. This recommendation does not apply to the minority of brainstem gliomas that are isocitrate dehydrogenase (IDH) mutant, for which temozolomide may be considered. (See <a class="local">'Chemotherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Despite aggressive therapy, the prognosis remains poor, with an average survival of less than one year. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="headingAnchor" id="H2960514804"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Mark Kieran, MD, PhD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Guillamo JS, Doz F, Delattre JY. Brain stem gliomas. Curr Opin Neurol 2001; 14:711.</a></li><li><a class="nounderline abstract_t">Monje M, Mitra SS, Freret ME, et al. Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proc Natl Acad Sci U S A 2011; 108:4453.</a></li><li><a class="nounderline abstract_t">Freeman CR, Farmer JP. Pediatric brain stem gliomas: A review. Int J Radiat Oncol Biol Phys 1998; 40:265.</a></li><li><a class="nounderline abstract_t">Rubin G, Michowitz S, Horev G, et al. Pediatric brain stem gliomas: An update. Childs Nerv Syst 1998; 14:167.</a></li><li><a class="nounderline abstract_t">Epstein FJ, Farmer JP. Brain-stem glioma growth patterns. J Neurosurg 1993; 78:408.</a></li><li><a class="nounderline abstract_t">Epstein F, Constantini S. Practical decisions in the treatment of pediatric brain stem tumors. Pediatr Neurosurg 1996; 24:24.</a></li><li><a class="nounderline abstract_t">Robertson PL, Allen JC, Abbott IR, et al. Cervicomedullary tumors in children: A distinct subset of brainstem gliomas. Neurology 1994; 44:1798.</a></li><li><a class="nounderline abstract_t">Pollack IF, Hoffman HJ, Humphreys RP, Becker L. The long-term outcome after surgical treatment of dorsally exophytic brain-stem gliomas. J Neurosurg 1993; 78:859.</a></li><li><a class="nounderline abstract_t">Fisher PG, Breiter SN, Carson BS, et al. A clinicopathologic reappraisal of brain stem tumor classification. Identification of pilocystic astrocytoma and fibrillary astrocytoma as distinct entities. Cancer 2000; 89:1569.</a></li><li><a class="nounderline abstract_t">Albright AL. Diffuse brainstem tumors: When is a biopsy necessary? Pediatr Neurosurg 1996; 24:252.</a></li><li><a class="nounderline abstract_t">Patil N, Kelly ME, Yeboa DN, et al. Epidemiology of brainstem high-grade gliomas in children and adolescents in the United States, 2000-2017. Neuro Oncol 2021; 23:990.</a></li><li><a class="nounderline abstract_t">Packer RJ. Brain tumors in children. Arch Neurol 1999; 56:421.</a></li><li><a class="nounderline abstract_t">Guillamo JS, Monjour A, Taillandier L, et al. Brainstem gliomas in adults: Prognostic factors and classification. Brain 2001; 124:2528.</a></li><li class="breakAll">Central Nervous System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, 2021.</li><li><a class="nounderline abstract_t">Singh S, Bhutani R, Jalali R. Leptomeninges as a site of relapse in locally controlled, diffuse pontine glioma with review of literature. Childs Nerv Syst 2007; 23:117.</a></li><li><a class="nounderline abstract_t">Gururangan S, McLaughlin CA, Brashears J, et al. Incidence and patterns of neuraxis metastases in children with diffuse pontine glioma. J Neurooncol 2006; 77:207.</a></li><li><a class="nounderline abstract_t">Zarghooni M, Bartels U, Lee E, et al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol 2010; 28:1337.</a></li><li><a class="nounderline abstract_t">Paugh BS, Broniscer A, Qu C, et al. Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol 2011; 29:3999.</a></li><li><a class="nounderline abstract_t">Wu G, Broniscer A, McEachron TA, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 2012; 44:251.</a></li><li><a class="nounderline abstract_t">Nikbakht H, Panditharatna E, Mikael LG, et al. Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. Nat Commun 2016; 7:11185.</a></li><li><a class="nounderline abstract_t">Hoffman LM, DeWire M, Ryall S, et al. Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: Implications for diagnostic biopsy and targeted therapeutics. Acta Neuropathol Commun 2016; 4:1.</a></li><li><a class="nounderline abstract_t">Lewis PW, Müller MM, Koletsky MS, et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 2013; 340:857.</a></li><li><a class="nounderline abstract_t">Zhang L, Chen LH, Wan H, et al. Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas. Nat Genet 2014; 46:726.</a></li><li><a class="nounderline abstract_t">Puget S, Philippe C, Bax DA, et al. Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas. PLoS One 2012; 7:e30313.</a></li><li><a class="nounderline abstract_t">Grill J, Puget S, Andreiuolo F, et al. Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma. Pediatr Blood Cancer 2012; 58:489.</a></li><li><a class="nounderline abstract_t">Wu G, Diaz AK, Paugh BS, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet 2014; 46:444.</a></li><li><a class="nounderline abstract_t">Taylor KR, Mackay A, Truffaux N, et al. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet 2014; 46:457.</a></li><li><a class="nounderline abstract_t">Fontebasso AM, Papillon-Cavanagh S, Schwartzentruber J, et al. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat Genet 2014; 46:462.</a></li><li><a class="nounderline abstract_t">Buczkowicz P, Hoeman C, Rakopoulos P, et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet 2014; 46:451.</a></li><li><a class="nounderline abstract_t">Vuong HG, Le HT, Ngo TNM, et al. H3K27M-mutant diffuse midline gliomas should be further molecularly stratified: an integrated analysis of 669 patients. J Neurooncol 2021; 155:225.</a></li><li><a class="nounderline abstract_t">Feng J, Hao S, Pan C, et al. The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults. Hum Pathol 2015; 46:1626.</a></li><li><a class="nounderline abstract_t">Banan R, Stichel D, Bleck A, et al. Infratentorial IDH-mutant astrocytoma is a distinct subtype. Acta Neuropathol 2020; 140:569.</a></li><li><a class="nounderline abstract_t">Picca A, Berzero G, Bielle F, et al. FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas. Neurology 2018; 90:e2086.</a></li><li><a class="nounderline abstract_t">van den Bent MJ, Tesileanu CMS, Wick W, et al. Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. Lancet Oncol 2021; 22:813.</a></li><li class="breakAll">WHO Classification of Tumours of the Central Nervous System, 4th ed, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), International Agency for Research on Cancer, 2016.</li><li><a class="nounderline abstract_t">Karremann M, Gielen GH, Hoffmann M, et al. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. Neuro Oncol 2018; 20:123.</a></li><li><a class="nounderline abstract_t">Meyronet D, Esteban-Mader M, Bonnet C, et al. Characteristics of H3 K27M-mutant gliomas in adults. Neuro Oncol 2017; 19:1127.</a></li><li><a class="nounderline abstract_t">Qiu T, Chanchotisatien A, Qin Z, et al. Imaging characteristics of adult H3 K27M-mutant gliomas. J Neurosurg 2019; 133:1662.</a></li><li><a class="nounderline abstract_t">Schreck KC, Ranjan S, Skorupan N, et al. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas. J Neurooncol 2019; 143:87.</a></li><li><a class="nounderline abstract_t">Grimaldi S, Harlay V, Appay R, et al. Adult H3K27M mutated thalamic glioma patients display a better prognosis than unmutated patients. J Neurooncol 2022; 156:615.</a></li><li><a class="nounderline abstract_t">Panditharatna E, Kilburn LB, Aboian MS, et al. Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy. Clin Cancer Res 2018; 24:5850.</a></li><li><a class="nounderline abstract_t">Broniscer A, Laningham FH, Kocak M, et al. Intratumoral hemorrhage among children with newly diagnosed, diffuse brainstem glioma. Cancer 2006; 106:1364.</a></li><li><a class="nounderline abstract_t">Krieger MD, Blüml S, McComb JG. Magnetic resonance spectroscopy of atypical diffuse pontine masses. Neurosurg Focus 2003; 15:E5.</a></li><li><a class="nounderline abstract_t">Hipp SJ, Steffen-Smith E, Hammoud D, et al. Predicting outcome of children with diffuse intrinsic pontine gliomas using multiparametric imaging. Neuro Oncol 2011; 13:904.</a></li><li><a class="nounderline abstract_t">Warren KE, Frank JA, Black JL, et al. Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors. J Clin Oncol 2000; 18:1020.</a></li><li><a class="nounderline abstract_t">Nadvi SS, Ebrahim FS, Corr P. The value of 201thallium-SPECT imaging in childhood brainstem gliomas. Pediatr Radiol 1998; 28:575.</a></li><li><a class="nounderline abstract_t">Kwon JW, Kim IO, Cheon JE, et al. Paediatric brain-stem gliomas: MRI, FDG-PET and histological grading correlation. Pediatr Radiol 2006; 36:959.</a></li><li><a class="nounderline abstract_t">Pichler R, Pichler J, Mustafa H, et al. Somatostatin-receptor positive brain stem glioma visualized by octreoscan. Neuro Endocrinol Lett 2007; 28:250.</a></li><li><a class="nounderline abstract_t">Hayward RM, Patronas N, Baker EH, et al. Inter-observer variability in the measurement of diffuse intrinsic pontine gliomas. J Neurooncol 2008; 90:57.</a></li><li><a class="nounderline abstract_t">Hargrave D, Chuang N, Bouffet E. Conventional MRI cannot predict survival in childhood diffuse intrinsic pontine glioma. J Neurooncol 2008; 86:313.</a></li><li><a class="nounderline abstract_t">Walker DA, Liu J, Kieran M, et al. A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the Delphi method. Neuro Oncol 2013; 15:462.</a></li><li><a class="nounderline abstract_t">Salvati M, Cervoni L. Carcinoma of the prostate: Brain stem metastasis as the only site of spread. Tumori 1997; 83:776.</a></li><li><a class="nounderline abstract_t">Liu AK, Macy ME, Foreman NK. Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas. Int J Radiat Oncol Biol Phys 2009; 75:1148.</a></li><li><a class="nounderline abstract_t">Albright AL, Packer RJ, Zimmerman R, et al. Magnetic resonance scans should replace biopsies for the diagnosis of diffuse brain stem gliomas: A report from the Children's Cancer Group. Neurosurgery 1993; 33:1026.</a></li><li><a class="nounderline abstract_t">Pincus DW, Richter EO, Yachnis AT, et al. Brainstem stereotactic biopsy sampling in children. J Neurosurg 2006; 104:108.</a></li><li><a class="nounderline abstract_t">Chitnavis B, Phipps K, Harkness W, Hayward R. Intrinsic brainstem tumours in childhood: A report of 35 children followed for a minimum of 5 years. Br J Neurosurg 1997; 11:206.</a></li><li><a class="nounderline abstract_t">Franzini A, Allegranza A, Melcarne A, et al. Serial stereotactic biopsy of brain stem expanding lesions. Considerations on 45 consecutive cases. Acta Neurochir Suppl (Wien) 1988; 42:170.</a></li><li><a class="nounderline abstract_t">Dellaretti M, Reyns N, Touzet G, et al. Diffuse brainstem glioma: Prognostic factors. J Neurosurg 2012; 117:810.</a></li><li><a class="nounderline abstract_t">Rajshekhar V, Chandy MJ. Computerized tomography-guided stereotactic surgery for brainstem masses: A risk-benefit analysis in 71 patients. J Neurosurg 1995; 82:976.</a></li><li><a class="nounderline abstract_t">Puget S, Beccaria K, Blauwblomme T, et al. Biopsy in a series of 130 pediatric diffuse intrinsic pontine gliomas. Childs Nerv Syst 2015; 31:1773.</a></li><li><a class="nounderline abstract_t">Roujeau T, Machado G, Garnett MR, et al. Stereotactic biopsy of diffuse pontine lesions in children. J Neurosurg 2007; 107:1.</a></li><li><a class="nounderline abstract_t">Pfaff E, El Damaty A, Balasubramanian GP, et al. Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: The INFORM study experience. Eur J Cancer 2019; 114:27.</a></li><li><a class="nounderline abstract_t">Gupta N, Goumnerova LC, Manley P, et al. Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. Neuro Oncol 2018; 20:1547.</a></li><li><a class="nounderline abstract_t">Schild SE, Stafford SL, Brown PD, et al. The results of radiotherapy for brainstem tumors. J Neurooncol 1998; 40:171.</a></li><li><a class="nounderline abstract_t">Donahue B, Allen J, Siffert J, et al. Patterns of recurrence in brain stem gliomas: Evidence for craniospinal dissemination. Int J Radiat Oncol Biol Phys 1998; 40:677.</a></li><li><a class="nounderline abstract_t">Sethi R, Allen J, Donahue B, et al. Prospective neuraxis MRI surveillance reveals a high risk of leptomeningeal dissemination in diffuse intrinsic pontine glioma. J Neurooncol 2011; 102:121.</a></li><li><a class="nounderline abstract_t">Janssens GO, Gidding CE, Van Lindert EJ, et al. The role of hypofractionation radiotherapy for diffuse intrinsic brainstem glioma in children: A pilot study. Int J Radiat Oncol Biol Phys 2009; 73:722.</a></li><li><a class="nounderline abstract_t">Negretti L, Bouchireb K, Levy-Piedbois C, et al. Hypofractionated radiotherapy in the treatment of diffuse intrinsic pontine glioma in children: A single institution's experience. J Neurooncol 2011; 104:773.</a></li><li><a class="nounderline abstract_t">Janssens GO, Jansen MH, Lauwers SJ, et al. Hypofractionation vs conventional radiation therapy for newly diagnosed diffuse intrinsic pontine glioma: A matched-cohort analysis. Int J Radiat Oncol Biol Phys 2013; 85:315.</a></li><li><a class="nounderline abstract_t">Zaghloul MS, Eldebawy E, Ahmed S, et al. Hypofractionated conformal radiotherapy for pediatric diffuse intrinsic pontine glioma (DIPG): A randomized controlled trial. Radiother Oncol 2014; 111:35.</a></li><li><a class="nounderline abstract_t">Zaghloul MS, Nasr A, Tolba M, et al. Hypofractionated Radiation Therapy For Diffuse Intrinsic Pontine Glioma: A Noninferiority Randomized Study Including 253 Children. Int J Radiat Oncol Biol Phys 2022; 113:360.</a></li><li><a class="nounderline abstract_t">Mandell LR, Kadota R, Freeman C, et al. There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: Results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys 1999; 43:959.</a></li><li><a class="nounderline abstract_t">Fisher PG, Donaldson SS. Hyperfractionated radiotherapy in the management of diffuse intrinsic brainstem tumors: When is enough enough? Int J Radiat Oncol Biol Phys 1999; 43:947.</a></li><li><a class="nounderline abstract_t">Freeman CR, Kepner J, Kun LE, et al. A detrimental effect of a combined chemotherapy-radiotherapy approach in children with diffuse intrinsic brain stem gliomas? Int J Radiat Oncol Biol Phys 2000; 47:561.</a></li><li><a class="nounderline abstract_t">Marcus KJ, Dutton SC, Barnes P, et al. A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma. Int J Radiat Oncol Biol Phys 2003; 55:1182.</a></li><li><a class="nounderline abstract_t">Walter AW, Gajjar A, Ochs JS, et al. Carboplatin and etoposide with hyperfractionated radiotherapy in children with newly diagnosed diffuse pontine gliomas: A phase I/II study. Med Pediatr Oncol 1998; 30:28.</a></li><li><a class="nounderline abstract_t">Jennings MT, Sposto R, Boyett JM, et al. Preradiation chemotherapy in primary high-risk brainstem tumors: Phase II study CCG-9941 of the Children's Cancer Group. J Clin Oncol 2002; 20:3431.</a></li><li><a class="nounderline abstract_t">Broniscer A, Iacono L, Chintagumpala M, et al. Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: Results of a multiinstitutional study (SJHG-98). Cancer 2005; 103:133.</a></li><li><a class="nounderline abstract_t">Chuba PJ, Zamarano L, Hamre M, et al. Permanent I-125 brain stem implants in children. Childs Nerv Syst 1998; 14:570.</a></li><li><a class="nounderline abstract_t">Fuchs I, Kreil W, Sutter B, et al. Gamma Knife radiosurgery of brainstem gliomas. Acta Neurochir Suppl 2002; 84:85.</a></li><li><a class="nounderline abstract_t">Fontanilla HP, Pinnix CC, Ketonen LM, et al. Palliative reirradiation for progressive diffuse intrinsic pontine glioma. Am J Clin Oncol 2012; 35:51.</a></li><li><a class="nounderline abstract_t">Lassaletta A, Strother D, Laperriere N, et al. Reirradiation in patients with diffuse intrinsic pontine gliomas: The Canadian experience. Pediatr Blood Cancer 2018; 65:e26988.</a></li><li><a class="nounderline abstract_t">Amsbaugh MJ, Mahajan A, Thall PF, et al. A phase 1/2 trial of reirradiation for diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys 2019; 104:144.</a></li><li><a class="nounderline abstract_t">Hargrave D, Bartels U, Bouffet E. Diffuse brainstem glioma in children: Critical review of clinical trials. Lancet Oncol 2006; 7:241.</a></li><li><a class="nounderline abstract_t">Korones DN, Fisher PG, Kretschmar C, et al. Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: A Children's Oncology Group phase II study. Pediatr Blood Cancer 2008; 50:227.</a></li><li><a class="nounderline abstract_t">Massimino M, Spreafico F, Biassoni V, et al. Diffuse pontine gliomas in children: Changing strategies, changing results? A mono-institutional 20-year experience. J Neurooncol 2008; 87:355.</a></li><li><a class="nounderline abstract_t">Cohen KJ, Heideman RL, Zhou T, et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: A report from the Children's Oncology Group. Neuro Oncol 2011; 13:410.</a></li><li><a class="nounderline abstract_t">Bailey S, Howman A, Wheatley K, et al. Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy--Results of a United Kingdom phase II trial (CNS 2007 04). Eur J Cancer 2013; 49:3856.</a></li><li><a class="nounderline abstract_t">Izzuddeen Y, Gupta S, Haresh KP, et al. Hypofractionated radiotherapy with temozolomide in diffuse intrinsic pontine gliomas: A randomized controlled trial. J Neurooncol 2020; 146:91.</a></li><li><a class="nounderline abstract_t">Sirachainan N, Pakakasama S, Visudithbhan A, et al. Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma. Neuro Oncol 2008; 10:577.</a></li><li><a class="nounderline abstract_t">Hashizume R, Andor N, Ihara Y, et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat Med 2014; 20:1394.</a></li><li><a class="nounderline abstract_t">Grasso CS, Tang Y, Truffaux N, et al. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat Med 2015; 21:555.</a></li><li><a class="nounderline abstract_t">Piunti A, Hashizume R, Morgan MA, et al. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Nat Med 2017; 23:493.</a></li><li><a class="nounderline abstract_t">Mohammad F, Weissmann S, Leblanc B, et al. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Nat Med 2017; 23:483.</a></li><li><a class="nounderline abstract_t">Mount CW, Majzner RG, Sundaresh S, et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas. Nat Med 2018; 24:572.</a></li><li><a class="nounderline abstract_t">Majzner RG, Ramakrishna S, Yeom KW, et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 2022; 603:934.</a></li><li><a class="nounderline abstract_t">Grassl N, Poschke I, Lindner K, et al. A H3K27M-targeted vaccine in adults with diffuse midline glioma. Nat Med 2023; 29:2586.</a></li><li><a class="nounderline abstract_t">Vitanza NA, Wilson AL, Huang W, et al. Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety. Cancer Discov 2023; 13:114.</a></li><li><a class="nounderline abstract_t">Graves PR, Aponte-Collazo LJ, Fennell EMJ, et al. Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues. ACS Chem Biol 2019; 14:1020.</a></li><li><a class="nounderline abstract_t">Arrillaga-Romany I, Chi AS, Allen JE, et al. A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget 2017; 8:79298.</a></li><li><a class="nounderline abstract_t">Chi AS, Tarapore RS, Hall MD, et al. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. J Neurooncol 2019; 145:97.</a></li><li class="breakAll">ClinicalTrials.gov. https://clinicaltrials.gov/ct2/results?cond=glioma&amp;term=ONC201&amp;cntry=&amp;state=&amp;city=&amp;dist= (Accessed on October 15, 2019).</li><li><a class="nounderline abstract_t">Gállego Pérez-Larraya J, Garcia-Moure M, Labiano S, et al. Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma. N Engl J Med 2022; 386:2471.</a></li><li><a class="nounderline abstract_t">Dunkel IJ, Doz F, Foreman NK, et al. Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908. Neuro Oncol 2023; 25:1530.</a></li><li><a class="nounderline abstract_t">Veldhuijzen van Zanten SEM, Lane A, Heymans MW, et al. External validation of the diffuse intrinsic pontine glioma survival prediction model: A collaborative report from the International DIPG Registry and the SIOPE DIPG Registry. J Neurooncol 2017; 134:231.</a></li><li><a class="nounderline abstract_t">Hassan H, Pinches A, Picton SV, Phillips RS. Survival rates and prognostic predictors of high grade brain stem gliomas in childhood: a systematic review and meta-analysis. J Neurooncol 2017; 135:13.</a></li><li><a class="nounderline abstract_t">Hoffman LM, Veldhuijzen van Zanten SEM, Colditz N, et al. Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. J Clin Oncol 2018; 36:1963.</a></li><li><a class="nounderline abstract_t">Jackson S, Patay Z, Howarth R, et al. Clinico-radiologic characteristics of long-term survivors of diffuse intrinsic pontine glioma. J Neurooncol 2013; 114:339.</a></li><li><a class="nounderline abstract_t">Broniscer A, Laningham FH, Sanders RP, et al. Young age may predict a better outcome for children with diffuse pontine glioma. Cancer 2008; 113:566.</a></li><li><a class="nounderline abstract_t">Erker C, Lane A, Chaney B, et al. Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. Neuro Oncol 2022; 24:141.</a></li><li><a class="nounderline abstract_t">Bartlett AL, Lane A, Chaney B, et al. Characteristics of children ≤36 months of age with DIPG: A report from the international DIPG registry. Neuro Oncol 2022; 24:2190.</a></li><li><a class="nounderline abstract_t">Sanford RA, Freeman CR, Burger P, Cohen ME. Prognostic criteria for experimental protocols in pediatric brainstem gliomas. Surg Neurol 1988; 30:276.</a></li><li><a class="nounderline abstract_t">Freeman CR, Bourgouin PM, Sanford RA, et al. Long term survivors of childhood brain stem gliomas treated with hyperfractionated radiotherapy. Clinical characteristics and treatment related toxicities. The Pediatric Oncology Group. Cancer 1996; 77:555.</a></li><li><a class="nounderline abstract_t">Selvapandian S, Rajshekhar V, Chandy MJ. Brainstem glioma: Comparative study of clinico-radiological presentation, pathology and outcome in children and adults. Acta Neurochir (Wien) 1999; 141:721.</a></li><li><a class="nounderline abstract_t">Landolfi JC, Thaler HT, DeAngelis LM. Adult brainstem gliomas. Neurology 1998; 51:1136.</a></li></ol></div><div id="topicVersionRevision">Topic 5229 Version 53.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11723378" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Brain stem gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21368213" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9457808" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pediatric brain stem gliomas: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9660117" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pediatric brain stem gliomas: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8433142" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Brain-stem glioma growth patterns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8817612" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Practical decisions in the treatment of pediatric brain stem tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7936224" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cervicomedullary tumors in children: a distinct subset of brainstem gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8487066" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The long-term outcome after surgical treatment of dorsally exophytic brain-stem gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11013373" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A clinicopathologic reappraisal of brain stem tumor classification. Identification of pilocystic astrocytoma and fibrillary astrocytoma as distinct entities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8933568" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Diffuse brainstem tumors: when is a biopsy necessary?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33346835" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Epidemiology of brainstem high-grade gliomas in children and adolescents in the United States, 2000-2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10199329" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Brain tumors in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11701605" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Brainstem gliomas in adults: prognostic factors and classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11701605" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Brainstem gliomas in adults: prognostic factors and classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16983574" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Leptomeninges as a site of relapse in locally controlled, diffuse pontine glioma with review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16568209" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Incidence and patterns of neuraxis metastases in children with diffuse pontine glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20142589" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21931021" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22286216" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27048880" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26727948" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23539183" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24880341" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22389665" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22190243" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24705251" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24705252" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24705250" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24705254" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34796414" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : H3K27M-mutant diffuse midline gliomas should be further molecularly stratified: an integrated analysis of 669 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26297251" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The H3.3 K27M mutation results in a poorer prognosis in brainstem gliomas than thalamic gliomas in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32776277" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Infratentorial IDH-mutant astrocytoma is a distinct subtype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29728520" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34000245" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34000245" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29016894" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28201752" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Characteristics of H3 K27M-mutant gliomas in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31731269" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Imaging characteristics of adult H3 K27M-mutant gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30864101" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34994963" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Adult H3K27M mutated thalamic glioma patients display a better prognosis than unmutated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30322880" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16463390" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Intratumoral hemorrhage among children with newly diagnosed, diffuse brainstem glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15355007" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Magnetic resonance spectroscopy of atypical diffuse pontine masses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21757444" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Predicting outcome of children with diffuse intrinsic pontine gliomas using multiparametric imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10694552" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9716624" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The value of 201thallium-SPECT imaging in childhood brainstem gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16847598" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Paediatric brain-stem gliomas: MRI, FDG-PET and histological grading correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17627256" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Somatostatin-receptor positive brain stem glioma visualized by octreoscan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18587536" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Inter-observer variability in the measurement of diffuse intrinsic pontine gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17909941" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Conventional MRI cannot predict survival in childhood diffuse intrinsic pontine glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23502427" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the Delphi method.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9349321" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Carcinoma of the prostate: brain stem metastasis as the only site of spread.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19857784" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8133987" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Magnetic resonance scans should replace biopsies for the diagnosis of diffuse brain stem gliomas: a report from the Children's Cancer Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16506498" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Brainstem stereotactic biopsy sampling in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9231007" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Intrinsic brainstem tumours in childhood: a report of 35 children followed for a minimum of 5 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3055827" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Serial stereotactic biopsy of brain stem expanding lesions. Considerations on 45 consecutive cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22937929" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Diffuse brainstem glioma: prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7760201" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Computerized tomography-guided stereotactic surgery for brainstem masses: a risk-benefit analysis in 71 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26351229" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Biopsy in a series of 130 pediatric diffuse intrinsic Pontine gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17647306" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Stereotactic biopsy of diffuse pontine lesions in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31022591" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29741745" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9892099" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The results of radiotherapy for brainstem tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9486619" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Patterns of recurrence in brain stem gliomas: evidence for craniospinal dissemination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20623246" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Prospective neuraxis MRI surveillance reveals a high risk of leptomeningeal dissemination in diffuse intrinsic pontine glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18990510" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The role of hypofractionation radiotherapy for diffuse intrinsic brainstem glioma in children: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21327862" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Hypofractionated radiotherapy in the treatment of diffuse intrinsic pontine glioma in children: a single institution's experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22682807" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Hypofractionation vs conventional radiation therapy for newly diagnosed diffuse intrinsic pontine glioma: a matched-cohort analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24560760" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Hypofractionated conformal radiotherapy for pediatric diffuse intrinsic pontine glioma (DIPG): a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35150788" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Hypofractionated Radiation Therapy For Diffuse Intrinsic Pontine Glioma: A Noninferiority Randomized Study Including 253 Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10192340" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10192338" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Hyperfractionated radiotherapy in the management of diffuse intrinsic brainstem tumors: when is enough enough?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10837936" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : A detrimental effect of a combined chemotherapy-radiotherapy approach in children with diffuse intrinsic brain stem gliomas?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12654425" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9371386" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Carboplatin and etoposide with hyperfractionated radiotherapy in children with newly diagnosed diffuse pontine gliomas: a phase I/II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12177103" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the Children's Cancer Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15565574" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9840381" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Permanent I-125 brain stem implants in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12379009" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Gamma Knife radiosurgery of brainstem gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21297433" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Palliative reirradiation for progressive diffuse intrinsic pontine glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29369515" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Reirradiation in patients with diffuse intrinsic pontine gliomas: The Canadian experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30610915" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : A Phase 1/2 Trial of Reirradiation for Diffuse Intrinsic Pontine Glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16510333" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Diffuse brainstem glioma in children: critical review of clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17278121" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a Children's Oncology Group phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18217208" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Diffuse pontine gliomas in children: changing strategies, changing results? A mono-institutional 20-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21345842" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24011536" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy--results of a United Kingdom phase II trial (CNS 2007 04).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31728883" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Hypofractionated radiotherapy with temozolomide in diffuse intrinsic pontine gliomas: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18559468" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25401693" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25939062" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Functionally defined therapeutic targets in diffuse intrinsic pontine glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28263307" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28263309" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29662203" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35130560" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37735561" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : A H3K27M-targeted vaccine in adults with diffuse midline glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36259971" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31021596" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29108308" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31456142" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31456142" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35767439" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36808285" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28560664" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : External validation of the diffuse intrinsic pontine glioma survival prediction model: a collaborative report from the International DIPG Registry and the SIOPE DIPG Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28681244" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Survival rates and prognostic predictors of high grade brain stem gliomas in childhood: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29746225" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23813229" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Clinico-radiologic characteristics of long-term survivors of diffuse intrinsic pontine glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18484645" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Young age may predict a better outcome for children with diffuse pontine glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34114629" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Characteristics of patients≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35552452" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Characteristics of children≤36 months of age with DIPG: A report from the international DIPG registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3175837" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Prognostic criteria for experimental protocols in pediatric brainstem gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8630965" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Long term survivors of childhood brain stem gliomas treated with hyperfractionated radiotherapy. Clinical characteristics and treatment related toxicities. The Pediatric Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10481783" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Brainstem glioma: comparative study of clinico-radiological presentation, pathology and outcome in children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9781543" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Adult brainstem gliomas.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
